Streetbeat News

BETRF

BetterLife Pharma Inc

https://pivotpharma.com/

CEO

Toni Rinow

Employees

4

Industry

Pharmaceutical Preparation Manufacturing

Open

0.06

Mkt cap

9.3M

Volume

40K

High

0.07

P/E Ratio

-2.40

52-wk high

0.15

Low

0.06

Div yield

N/A

52-wk low

0.04

Ahmad Doroudian has filed an early warning report regarding his ownership of 14,250,461 common shares in BetterLife Pharma Inc., representing approximately 11.01% of the company's shares. This investment reflects his long-term view of the company, and he may adjust his holdings based on market conditions.

Portfolio Pulse from

November 20, 2024 | 2:30 am

The article provides a comprehensive roundup of recent developments in the psychedelics field, including research findings, global regulatory perspectives, therapeutic applications, and business news. Key highlights include potential roles of psilocybin in dementia prevention and psychological flexibility, global legalization trends, and various companies' strategic moves such as voluntary delistings, partnership agreements, financial results, and patent filings related to psychedelic therapies.

Portfolio Pulse from Lara Goldstein

April 17, 2024 | 1:13 pm

The Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored a Psychedelic Science conference in Denver, attracting over 12,000 attendees. New York Mets owner Steve Cohen announced a $5 million grant for MAPS’ ongoing clinical studies toward FDA approval of MDMA-assisted therapy for PTSD. Toms Shoes founder Blake Mycoskie pledged to donate and invest $100 million in organizations and projects advancing psychedelic-assisted therapies. SEMRush (NYSE:SEMR) analysis revealed a shift in America's consciousness towards psychedelics and cannabis. Several companies received regulatory approvals and patents, and announced partnerships and financial results.

Portfolio Pulse from Lara Goldstein

July 04, 2023 | 2:21 pm

BetterLife Pharma Inc. (OTCQB:BETRF) is fast-tracking its U.S. patent application for non-hallucinogenic LSD derivatives, including its 2-bromo-LSD derivative BETR-001, which is expected to begin clinical trials for Major Depressive Disorder. The patent covers the composition, treatment uses, and a novel production method. The company's CEO, Dr. Ahmad Doroudian, highlighted the compound's neuroplasticity properties and efficacy in preclinical models of depression, anxiety, and pain. Another biotech company, PharmaTher Holdings (OTC:PHRRF), recently fast-tracked an application for its proprietary racemic ketamine, KETARX, for the treatment of levodopa-induced dyskinesia in Parkinson’s disease.

Portfolio Pulse from Lara Goldstein

June 28, 2023 | 7:01 pm

The Energia Foundation is hosting a psychedelics education event in Dubai, while new research finds a key receptor for treating depression with psychedelics. Creso Pharma (OTC:COPHF) signs an LOI for importing Swiss MDMA and psilocybin therapeutics to Australia. AdvisorShares Psychedelics ETF (NYSE:PSIL) shows a consistent upward trend.

Portfolio Pulse from Lara Goldstein

June 13, 2023 | 2:31 pm

BetterLife Pharma's non-hallucinogenic LSD derivative, BETR-001, is progressing through IND-enabling studies for Major Depressive Disorder. Braxia Scientific reports a 26.2% YoY growth in treatment volumes and plans to restructure its business, including slowing down its U.S.-based telemedicine business KetaMD.

Portfolio Pulse from Lara Goldstein

June 09, 2023 | 8:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.